Our study possesses several strengths: (i) A clear research objective of assessing the efficacy of anti-CGRP mAbs in patients unresponsive to conventional migraine therapies; (ii) rigorous inclusion and exclusion criteria; (iii) a combination of patient-reported outcomes (i.e., DHI) and objective vestibular assessments (i.e., videonystagmography), contributing to a comprehensive evaluation of treatment outcomes; (iv) a direct comparison between anti-CGRP mAbs and conventional migraine treatments within the same cohort, providing valuable insights into treatment effectiveness. This evidence concerns the gene CALCA and migraine disorder.